Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQH2722 injection in chronic rhinosinusitis with or without nasal polyps
CTR20233328Phase 2Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2722 in chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis (CRS), sponsored by Nanjing Shunxin Pharmaceutical. Started Oct 2023; status: completed.
02
Drugs
TQH2722
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on CTR20233328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233328.